PRT-811

Pathos AI Raises $365 Million to Advance AI-Driven Oncology Drug Development

8 days ago

• Pathos AI secured $365 million in Series D financing, reaching a post-money valuation of $1.6 billion to expand its AI-enabled platform for oncology drug development. • The company is developing the largest multimodal foundation model in oncology, leveraging clinical, molecular, and imaging data to improve asset selection and clinical trial design. • Under CEO Iker Huerga's leadership, Pathos aims to transform drug development by combining advanced AI with deep clinical insights to accelerate the path from molecule to medicine.

Pathos AI Secures $62M Series C Funding to Advance AI-Powered Drug Development

7 months ago

• Pathos AI closed an oversubscribed $62M Series C round, led by NEA, to expand its AI-powered drug development platform and advance its precision oncology therapeutics. • The funding will support the expansion of Pathos' team and accelerate the clinical development of assets like P-500, a brain-penetrant PRMT5 inhibitor, for IDH+ high-grade glioma. • Pathos leverages its PathOS™ platform to identify biological mechanisms driving cancer and patient outcomes, aiming to improve patient selection and clinical trial success. • With $102M in total funding, Pathos plans to acquire additional clinical-stage oncology assets and partner with biopharma to enhance precision medicine.

Pathos AI Raises $365 Million to Advance AI-Driven Oncology Drug Development

Pathos AI Secures $62M Series C Funding to Advance AI-Powered Drug Development

Drug Development Updates